Addressing global health challenges: the pharmaphorum podcastFor episode 11 of the pharmaphorum podcast our CEO and founder Dr Paul Tunnah took the helm to Share XAddressing global health challenges: the pharmaphorum podcasthttps://pharmaphorum.com/podcast/iavi-global-health-challenges/
ASCO 2019 – Kantar considers MacroGenics’ phase 3 SOPHIA trialKantar analyst Katie Stockstill discusses the results of phase 3 SOPHIA trial that were presented on the last Share XASCO 2019 – Kantar considers MacroGenics’ phase 3 SOPHIA trialhttps://pharmaphorum.com/spotlight/asco-2019-and-the-future-of-oncology/kantar-macrogenics-phase-3-sophia-trial/
ASCO 2019 – phase I data generates hope for the futureSometimes interesting stories from the ASCO conference are the phase I data that generates hope for the future. Share XASCO 2019 – phase I data generates hope for the futurehttps://pharmaphorum.com/spotlight/asco-2019-and-the-future-of-oncology/amgen-kras-amg510-phase-i-data/
ASCO 2019 – Enfortumab comes out fighting in bladder cancerAt ASCO 2019, results were presented from the phase II EV-201 trial, which evaluated antibody drug conjugate (ADC) Share XASCO 2019 – Enfortumab comes out fighting in bladder cancerhttps://pharmaphorum.com/video/asco-2019-enfortumab-bladder-cancer/
ASCO 2019 – Kantar highlights a selection of exciting Phase I and Phase II resultsAt ASCO, a lot of attention is given to the results of the large, clinical practices changing phase Share XASCO 2019 – Kantar highlights a selection of exciting Phase I and Phase II resultshttps://pharmaphorum.com/video/asco-2019-results-clinical-practices-changing-phase-iii-studies/
ASCO 2019 – Kantar debates results from the KEYNOTE-062 trialThere were a number of debate-worthy outcomes from the KEYNOTE-062 trial that was presented at ASCO 2019 in Share XASCO 2019 – Kantar debates results from the KEYNOTE-062 trialhttps://pharmaphorum.com/spotlight/asco-2019-and-the-future-of-oncology/asco-2019-kantar-debate-results-from-keynote-062-trial/
ASCO 2019 – Kantar reviews results from phase 3 POLO trialLynparza is paving new ground in pancreatic cancer, aiming to establish a maintenance setting and patient segmentation based Share XASCO 2019 – Kantar reviews results from phase 3 POLO trialhttps://pharmaphorum.com/spotlight/asco-2019-and-the-future-of-oncology/asco-2019-kantar-phase-3-polo-trial/
ASCO 2019 – Kantar reviews multiple myeloma showdownDay three of ASCO 2019 saw a showdown between two anti-CD38 compounds in multiple myeloma, Janssen’s Darzalex and Share XASCO 2019 – Kantar reviews multiple myeloma showdownhttps://pharmaphorum.com/spotlight/asco-2019-and-the-future-of-oncology/asco-2019-kantar-multiplemyeloma-data/
ASCO 2019 – Kantar takes a first look at interim data from the Phase 3 TITAN trialWill Erleada take the lead in metastatic CSPC? New interim data at ASCO 2019 from the Phase 3 Share XASCO 2019 – Kantar takes a first look at interim data from the Phase 3 TITAN trialhttps://pharmaphorum.com/spotlight/asco-2019-and-the-future-of-oncology/asco-2019-kantar-interim-data-phase-3-titan-trial/
